Navigation Links
Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
Date:4/15/2008

Highly Anticipated ARCHITECT(R) i1000SR(R) Analyzer Enhances Workflow and

Boosts Laboratory Productivity

ABBOTT PARK, Ill., April 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) has introduced the ARCHITECT(R) i1000SR(R) immunochemistry analyzer, expanding its ARCHITECT family of diagnostics instrument systems for clinical laboratories. Designed for labs that typically perform less than 200 immunoassay tests per day, the instrument addresses many of the workflow challenges common in today's laboratories.

With the increased demand for diagnostic testing, laboratories, both large and small, need to process tests as quickly and efficiently as possible. By providing continuous access to reagents and samples while the instrument is running, the ARCHITECT i1000SR enhances laboratory productivity. Additionally, a wide test menu, user-friendly software and low maintenance make it easy to train new laboratory personnel on the instrument's operation.

"Because time and ease of use are so critical in the testing environment, Abbott worked extensively with customers very early in the development phase and designed an instrument that could help smaller labs overcome the same productivity obstacles faced by larger labs," said Cass Grandone, divisional vice president, Systems Development, Abbott Diagnostics. "The ARCHITECT i1000SR analyzer is ideal for facilities running less than 200 tests per day and offers productivity benefits, such as highly efficient sample processing, usually reserved for larger testing facilities. Since ARCHITECT utilizes common reagents, consumables and software user interfaces, larger laboratories may be interested in using the instrument as a back-up system to the i2000SR."

The ARCHITECT i1000SR analyzer can process up to 100 tests per hour. The instrument accommodates 65 patient samples and has the capability to prioritize emergency test results and turn them around in less than 16 minutes.

Similar to ARCHITECT ci8200(TM) and ci16200(TM), the analyzer is part of the ARCHITECT family, with important features including:

-- True Family Commonality. Key components, including reagents, can be

shared across ARCHITECT instruments and multiple testing sites for

effective and efficient patient care.

-- Enhanced Assay and System Dynamics. ARCHITECT instruments offer

advanced technology, which means laboratories, physicians and,

ultimately, patients can be confident in the accuracy of test results.

-- Integration without Compromise. The ARCHITECT family combines

immunoassay and clinical chemistry technologies without jeopardizing

key performance, including turnaround time or accuracy of results.

Abbott recently introduced three other instruments in the ARCHITECT family: the ARCHITECT c16000(TM) clinical chemistry analyzer, the ARCHITECT ci16200, an integrated immunoassay and clinical chemistry analyzer, and the ARCHITECT i4000SR(TM) analyzer for high volume immunoassay testing.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
3. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
4. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
5. New type of drug shows promise in attacking melanoma in an innovative way
6. Astra Tech Acquires an Innovative Dental CAD/CAM Company
7. Astra Tech Acquires Innovative Dental Digital Technology Company
8. Prime Minister views innovative health technology at Imperial College London
9. AHFs Innovative Stay Negative HIV Prevention Campaign Successfully Breaks Through to Target Audience
10. Mecklenburg EMS Agency Launches Innovative Program to Pay Future EMTs While They Train
11. Green Pet Products Introduces a New, Innovative Process to the Small Animal and Bird Litter/Bedding Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... 2017 , ... Momkus McCluskey Roberts LLC recently announced it was ... of the firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined ... matters of employment litigation, commercial litigation and business disputes. Her experience includes all aspects ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... Group, a Florida-based oncology business advisor to oncology practices, announced today the results ... amount of attributable savings from resolving critical clinical issues that would have otherwise ...
(Date:8/16/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... August 16, 2017 ... ... list of the fastest growing companies in the U.S. for the second year in ... shown strong growth over the past three years. , “To be on the list ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, McDaniel & ... years in business this year, and they’re marking the milestone by undertaking a ... their patients. , It stands to reason that, given the central importance ...
(Date:8/16/2017)... ... 16, 2017 , ... The Southeastern Telehealth Resource Center at ... renewing its funding from the Health Resources and Services Administration (HRSA), part of ... fourth time the HRSA administration has renewed its financial support to GPT since ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: